The Liquid Biopsy That Found Pancreatic Cancer Early Has a Bigger Regulatory Problem Than Its Science

Ninety percent of pancreatic ductal adenocarcinoma patients receive their diagnosis after the cancer has already spread. That number has barely moved in decades, and it explains almost everything about why the five-year survival rate for PDAC sits at a grim 13 percent, per the American Cancer Society’s 2024 Cancer Facts & Figures Report. Into that context, City of Hope’s investigational liquid biopsy platform PANXEON just published performance data that genuinely warrants attention: 87% sensitivity for stage 1 and stage 2 PDAC, with a 3% false-positive rate in low-risk groups.

Those numbers would be remarkable for any cancer type. For pancreatic cancer, where catching the disease before it metastasizes is the only scenario where surgical resection becomes viable, they represent a potential inflection point in how the field thinks about population-level screening.

But the science solving the detection problem may be the easier half of what comes next.

What the Performance Data Actually Says

Open the PANXEON dataset and read it carefully, because the headline sensitivity figure obscures a critical operational variable. The 87% sensitivity applies to stages 1 and 2 combined. The false-positive rate diverges sharply by risk population: 3% in low-risk groups, 16% in high-risk groups. That 16% figure is not a trivial footnote. In a screening program targeting high-risk individuals, first-degree relatives of PDAC patients, carriers of relevant germline variants, individuals with new-onset diabetes, a 16% false-positive rate translates directly into diagnostic workups, patient anxiety, endoscopic ultrasounds, and downstream costs that the healthcare system will scrutinize before it reimburses anything at scale.

To put a number on what “downstream costs” means: the mean total direct medical cost for pancreatic cancer treatment per Medicare patient runs to $65,500, with costs for resectable locoregional disease running higher still due to surgical intervention. A false-positive cascade in a high-risk cohort does not approach those figures, but it adds enough noise to a payer cost-effectiveness model to complicate coverage decisions substantially. Payers will run that arithmetic before any national coverage determination.

The platform also detected high-grade dysplasia, a precancerous state, which is clinically meaningful but introduces a separate regulatory category question: is PANXEON a cancer detection tool or a dysplasia surveillance tool? The FDA will want to know, and the answer changes the intended use statement, which changes the approval pathway, which changes the trial design requirements for every validation study that follows.

The Regulatory Architecture Problem

Here is the counterintuitive reality that the liquid biopsy field keeps learning the hard way: strong analytical performance does not accelerate regulatory approval; it frequently complicates it. The FDA’s companion diagnostic framework, formalized in the agency’s June 2023 guidance on oncology drug products used with certain in vitro diagnostics, describes a voluntary pilot program designed to facilitate co-development of therapeutics and their companion tests. PANXEON is not a companion diagnostic in the traditional sense, it is a screening tool without a paired therapeutic, which means the co-development pathway does not cleanly apply.

That distinction matters enormously for trial design. A companion diagnostic developed alongside a targeted therapy can leverage the drug’s pivotal trial as part of the device’s evidentiary package. A standalone screening biomarker has no such anchor. It must demonstrate clinical validity and clinical utility independently, which requires a prospective study design with endpoints the FDA will negotiate through De Novo or PMA review, not an abbreviated pathway.

The CellSearch CTC enumeration platform, which received initial FDA clearance for monitoring advanced metastatic breast cancer and later for colorectal and prostate cancers,, spent years navigating exactly this gap between analytical performance and clinical utility demonstration. CellSearch could enumerate circulating tumor cells accurately. What it took considerably longer to establish was whether that enumeration actually changed clinical decision-making in a way that improved patient outcomes. Payers and the FDA asked that question repeatedly, and the answers drove post-market requirements that extended the platform’s commercial uncertainty well past its initial clearance.

PANXEON now faces a structurally similar question, posed with considerably higher stakes. Screening an asymptomatic population for a disease with a 13% five-year survival rate carries a different risk-benefit calculus than monitoring a known metastatic patient. The FDA will demand a prospective dataset demonstrating that acting on a positive PANXEON result, through increased surveillance, earlier surgical evaluation, or enrollment into prevention trials, produces a measurable improvement in clinical outcomes. Analytical sensitivity alone does not satisfy that bar.

What a Credible Validation Path Looks Like

Sponsors building the regulatory strategy for a platform like PANXEON face three design decisions that will determine whether their clinical utility data is accepted on first submission or triggers a complete response letter.

First, the risk stratification architecture must be locked before pivotal enrollment begins. The 3% versus 16% false-positive rate divergence across risk groups is exactly the kind of finding a reviewer will use to require subgroup-specific labeling claims. If the sponsor wants a single intended use statement covering both low-risk and high-risk populations, the trial must be powered to support that claim in both strata simultaneously, not sequentially in post-hoc analyses.

Second, multi-country regulatory pathways require coordinated dossier design from day one, not as an afterthought following US approval. The EMA’s regulation of in vitro diagnostics under IVDR, which began phased application from May 2022,, applies a performance class framework that diverges from the FDA’s intended use and predicate-based structure. A PANXEON submission built exclusively around FDA evidentiary requirements will require significant restructuring for the EMA, a problem that costs sponsors 12 to 18 months of additional development time when not anticipated in protocol design.

Third, the clinical utility endpoint cannot be time-to-surgery alone. The FDA has signaled in recent advisory committee discussions that cancer screening tools need to demonstrate impact on stage migration at the population level, meaning the pivotal study design should include a comparator arm reflecting current standard-of-care diagnosis timing, with pre-specified analysis of what percentage of PANXEON-detected cases presented at stage 1 or 2 versus what historical registry data would predict for the same population. That is a complex trial design problem, and it requires an adaptive framework with pre-specified interim analyses to allow early stopping for efficacy or futility without inflating Type I error.

The PANXEON performance data published this month represents the kind of signal the field has been waiting for. The 87% sensitivity in early-stage PDAC, if it holds in a prospective registry trial of sufficient scale, could genuinely shift the staging distribution at diagnosis. But the path from a promising biomarker study to an FDA-cleared, CMS-reimbursed screening test for asymptomatic high-risk individuals runs through regulatory terrain that has stopped technically superior platforms before. The sponsors who get there first will be the ones who treat the regulatory strategy as a trial design input, not a submission task, and who lock their intended use statement before they enroll their first subject.

References

1. Nature Medicine, “Liquid biopsy for early detection of pancreatic ductal adenocarcinoma”
2. Hirshberg Foundation for Pancreatic Cancer Research, “5-Year Survival Rate Increases Again, Landing at 13%” (January 17, 2024)
3. PMC / NCBI, “Mean total direct medical cost for pancreatic cancer treatment per Medicare patient: $65,500”
4. Oncology Central, “Liquid biopsy could detect pancreatic ductal adenocarcinoma at its earliest stages” (PANXEON 87% sensitivity, false-positive rates)
5. FDA, “Companion Diagnostics” guidance page, including June 21, 2023 pilot program guidance for oncology drug products used with certain IVD tests
6. CLP Magazine, “Panxeon Liquid Biopsy Detects Early-Stage Pancreatic Cancer”
7. Medpace, “The Utility of Liquid Biopsy in Oncology Clinical Trials” (including CellSearch CTC platform FDA approval history)